<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">AIDS Care</journal-id><journal-id journal-id-type="iso-abbrev">AIDS Care</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>AIDS care</journal-title></journal-title-group><issn pub-type="ppub">0954-0121</issn><issn pub-type="epub">1360-0451</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10272289</article-id><article-id pub-id-type="pmcid-ver">PMC10272289.319</article-id><article-id pub-id-type="pmcaid">10272289</article-id><article-id pub-id-type="pmcaiid">10272289</article-id><article-id pub-id-type="manuscript-id">NIHMS1853410</article-id><article-id pub-id-type="pmid">36524873</article-id><article-id pub-id-type="doi">10.1080/09540121.2022.2148626</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS1853410</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA1853410</article-id><article-version article-version-type="pmc-version">319</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Hypertension burden, treatment, and control among people with HIV at a clinical care center in the Southeastern US, 2014&#8211;2019</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Remch</surname><given-names initials="M">Molly</given-names></name><degrees>MSPH</degrees><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Franceschini</surname><given-names initials="N">Nora</given-names></name><degrees>MD, MPH</degrees><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Davy-Mendez</surname><given-names initials="T">Thibaut</given-names></name><degrees>PhD</degrees><xref rid="A2" ref-type="aff">2</xref><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Floris-Moore</surname><given-names initials="M">Michelle</given-names></name><degrees>MD, MS</degrees><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Napravnik</surname><given-names initials="S">Sonia</given-names></name><degrees>PhD</degrees><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, USA</aff><aff id="A2"><label>2</label>Division of Infectious Diseases, Department of Medicine, School of Medicine, University of North Carolina, Chapel Hill, NC, USA</aff><aff id="A3"><label>3</label>Department of Psychiatry and Behavioral Sciences, School of Medicine, University of California, San Francisco, CA, USA</aff><author-notes><corresp id="CR1"><bold>Correspondence and requests for reprints should be addressed to:</bold> Molly Remch, MSPH, 2101 McGavran-Greenberg Hall, CB #7435, Chapel Hill, NC 27599-7435, Phone: 919.966.7430, Fax: 919.966.2089, <email>mremch@email.unc.edu</email></corresp></author-notes><pub-date pub-type="ppub"><month>10</month><year>2023</year></pub-date><pub-date pub-type="epub"><day>16</day><month>12</month><year>2022</year></pub-date><volume>35</volume><issue>10</issue><issue-id pub-id-type="pmc-issue-id">438380</issue-id><fpage>1594</fpage><lpage>1603</lpage><pub-history><event event-type="nihms-submitted"><date><day>15</day><month>12</month><year>2022</year></date></event><event event-type="pmc-release"><date><day>01</day><month>10</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>01</day><month>10</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-10-01 00:25:29.690"><day>01</day><month>10</month><year>2024</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1853410.pdf"/><abstract id="ABS1"><p id="P1">Hypertension management outcomes in people with HIV (PWH) are not well characterized, despite high hypertension burden. We assessed hypertension prevalence, incidence, treatment, and outcomes among patients with HIV at a clinical center in the southeastern US, from 2014 to 2019. To identify characteristics associated with treatment and outcomes, we estimated adjusted risk ratios (aRR) and 95% confidence intervals (CI). Among 2,274 patients, 72% were cisgender men, 56% non-Hispanic Black, median age 47 years, 48% MSM, 12% had CD4 cell count &lt;200 cells/&#956;l, 72% HIV RNA level &lt;400 copies/mL and 39% prevalent hypertension. Hypertension incidence rate was 6.3/100 person-years (95% CI, 5.6&#8211;7.0). Among incident hypertension cases (n=275), 16% (95% CI, 11&#8211;20) initiated an antihypertensive within one year. Compared to non-Hispanic white patients, Hispanic (aRR, 6.68; 95% CI, 1.50&#8211;29.74) and non-Hispanic Black patients (aRR, 2.18; 95% CI, 0.91&#8211;5.24) were more likely to initiate an antihypertensive. Among patients initiating an antihypertensive (n=178), 63% (95% CI 56&#8211;70) experienced blood pressure control within one year. Patients with HIV experienced a high burden of hypertension with notable delays in antihypertensive initiation, as well as, gaps in achieving blood pressure control, highlighting opportunities for interventions designed to minimize delays in controlling hypertension in this vulnerable population.</p></abstract><kwd-group><kwd>cardiovascular disease</kwd><kwd>clinical cohort</kwd><kwd>HIV</kwd><kwd>hypertension</kwd><kwd>people with HIV</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>